Pochop Pavel, Darsova Denisa, Kukacka Jiri, Tesfaye Hundie, Vajner Ludek, Uhlik Jiri, Kodetová Daniela, Malis Josef, Dotrelova Dagmar
Department of Ophthalmology for Children and Adults, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
Eur J Ophthalmol. 2010 Jul-Aug;20(4):745-51. doi: 10.1177/112067211002000416.
To determine platinum (Pt) concentrations and area under the concentration versus time curve (AUC) of the vitreous humor after periocular or transcorneal intravitreal administration of carboplatin in rabbits.
Eighteen albino rabbits were included in an in vivo experiment. Each animal received a single dose of either 30 mg of carboplatin by periocular injection (POI30 group: n = 6) or 15 mg by periocular injection (PI15 group: n = 6), or 0.05 mg by transcorneal intravitreal injection (TII group: n = 6), respectively, into the right eye. Vitreous humor from the right eyes and plasma samples were collected post dose at 1, 2, 6, 24, 48, 168, and 336 hours or 448 hours, respectively. Flameless atomic absorption spectroscopy was employed to analyze total platinum concentrations in blood and vitreous humor. AUC was calculated using the trapezoidal rule.
Pt concentration was mostly < 1 mg/L (0-3.15 mg/L) in the vitreous humor samples and > or = 2 mg/L (2.33-7.3 mg/L) in the blood samples 1 hour after administration in POI groups. Markedly higher Pt concentrations were found 1 hour after intravitreal (TII) administration (10.285-66.759 mg/L) and decreased below 1 mg/L no less than 168 hours after administration. The mean AUC for Pt in vitreous humor was significantly lower (p = 0.0001) after both POI30 and P0I15 administration compared to TII route (8.955 +/- 2.464 mg/L/min).
These findings proved that intravitreal carboplatin delivery enables the achievement of relatively stable concentrations and AUC of platinum in the rabbit vitreous humor. This moreover suggests that transcorneal intravitreal delivery of carboplatin aiming to treat retinoblastoma vitreous seeding is a promising mode of chemotherapy.
测定兔眼周或经角膜玻璃体内注射卡铂后玻璃体液中铂(Pt)的浓度及浓度-时间曲线下面积(AUC)。
18只白化兔纳入体内实验。每只动物右眼分别接受单次剂量的30mg卡铂眼周注射(POI30组:n = 6)、15mg卡铂眼周注射(PI15组:n = 6)或0.05mg经角膜玻璃体内注射(TII组:n = 6)。给药后分别于1、2、6、24、48、168、336小时或448小时采集右眼玻璃体液和血浆样本。采用无火焰原子吸收光谱法分析血液和玻璃体液中的总铂浓度。使用梯形法则计算AUC。
POI组给药1小时后,玻璃体液样本中Pt浓度大多<1mg/L(0 - 3.15mg/L),血液样本中Pt浓度≥2mg/L(2.33 - 7.3mg/L)。玻璃体内(TII)注射给药1小时后发现Pt浓度明显更高(10.285 - 66.759mg/L),给药后不少于168小时降至<1mg/L。与TII途径(8.955±2.464mg/L/min)相比,POI30和POI15给药后玻璃体液中Pt的平均AUC显著更低(p = 0.0001)。
这些发现证明玻璃体内注射卡铂能够在兔玻璃体液中实现相对稳定的铂浓度和AUC。这还表明,旨在治疗视网膜母细胞瘤玻璃体种植的经角膜玻璃体内注射卡铂是一种有前景的化疗方式。